Overview

Price chart · mood · technical indicators

KRYS

Krystal Biotech Incstock Healthcare

Biotechnology

$301.82127.58%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$127.99$319.48

Current: $301.82

Idea: EMA

1Y Return

+68.7%

Sharpe 3Y

0.65

Market Comparison

vs Healthcare Sector & Biotechnology Industry

KRYS

+127.58%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio40.90Forward 45.25

EPS (TTM)$7.4652.5% YoY

Profit margin53.9%HEALTHCARE

Market cap$8.99BMid cap

Wall Street coverage

$322.78median target· current $167.63 (+92.6%)11 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 45.25
PEG ratio: —
P/B: 7.15
P/S (TTM): 21.43
EV/EBITDA: 44.82

Profitability & growth

ROE (TTM): 19.9%
Operating margin: 46.1%
Revenue growth YoY: 31.9%
Dividend yield: —
Beta: 0.49

Last earnings

May 4, 2026 · Estimate $1.42 · Reported $1.83

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Krystal Biotech Inc

Company profile

Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 2100 WHARTON STREET, PITTSBURGH, PA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$8.99B

Shares outstanding$29.5M

52W high$319.48

52W low$124.00

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

KRYS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $364

KRYS Technical Analysis & Stock Price Forecast

Exploring High Growth Tech Stocks In The US Market May 2026

Exploring High Growth Tech Stocks In The US Market May 2026

Insider Sell: John Thomas Sells Shares of Krystal Biotech Inc (KRYS)

Krystal Biotech EVP, general counsel sells $193,903 in shares By Investing.com

Krystal Biotech EVP, general counsel sells $193,903 in shares

KRYS: Future Returns Will Reflect UK Approval And Debated Execution Risks

Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)?

Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)?

Krystal Biotech (KRYS) Investor Outlook: Robust Growth Prospects with 8.32% Potential Upside

Precision Trading with Krystal Biotech Inc. (KRYS) Risk Zones

BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $364

Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end

Dow Soars 600 Points As Oil, Bond Yields Plunge: Krystal Biotech, Morgan Stanley, Marriott In Focus

The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability

Krystal Biotech Inc stock (US5012681064): HC Wainwright confirms Buy as UK clears VYJUVEK

Krystal Biotech gains regulatory approval to sell gene therapy in the United Kingdom

Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com

Krystal Biotech's (KRYS) Buy Rating Reaffirmed at HC Wainwright

About Krystal Biotech Inc

Classification

Company profile

KRYS

Market Comparison

KRYS Market Analysis

Overview

KRYS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $364

KRYS Technical Analysis & Stock Price Forecast

Exploring High Growth Tech Stocks In The US Market May 2026

Exploring High Growth Tech Stocks In The US Market May 2026

Insider Sell: John Thomas Sells Shares of Krystal Biotech Inc (KRYS)

Krystal Biotech EVP, general counsel sells $193,903 in shares By Investing.com

Krystal Biotech EVP, general counsel sells $193,903 in shares

KRYS: Future Returns Will Reflect UK Approval And Debated Execution Risks

Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)?

Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)?

Krystal Biotech (KRYS) Investor Outlook: Robust Growth Prospects with 8.32% Potential Upside

Precision Trading with Krystal Biotech Inc. (KRYS) Risk Zones

BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $364

Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end

Dow Soars 600 Points As Oil, Bond Yields Plunge: Krystal Biotech, Morgan Stanley, Marriott In Focus

The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability

Krystal Biotech Inc stock (US5012681064): HC Wainwright confirms Buy as UK clears VYJUVEK

Krystal Biotech gains regulatory approval to sell gene therapy in the United Kingdom

Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com

Krystal Biotech's (KRYS) Buy Rating Reaffirmed at HC Wainwright

About Krystal Biotech Inc

Classification

Company profile

KRYS

Market Comparison